TY  - BOOK
AU  - Colice, Gene L
TI  - The misuse of asthma drugs. [Review]
SN  - 1747-6348
PY  - 2013///
KW  - *Anti-Asthmatic Agents/tu [Therapeutic Use]
KW  - *Asthma/dt [Drug Therapy]
KW  - *Inappropriate Prescribing
KW  - *Lung/de [Drug Effects]
KW  - Anti-Asthmatic Agents/ae [Adverse Effects]
KW  - Anti-Asthmatic Agents/ec [Economics]
KW  - Asthma/di [Diagnosis]
KW  - Asthma/ec [Economics]
KW  - Asthma/pp [Physiopathology]
KW  - Attitude of Health Personnel
KW  - Disease Progression
KW  - Drug Costs
KW  - Drug Utilization
KW  - Guideline Adherence
KW  - Health Knowledge, Attitudes, Practice
KW  - Humans
KW  - Inappropriate Prescribing/ec [Economics]
KW  - Lung/pp [Physiopathology]
KW  - Patient Selection
KW  - Physician's Practice Patterns
KW  - Practice Guidelines as Topic
KW  - Predictive Value of Tests
KW  - Risk Assessment
KW  - Risk Factors
KW  - Severity of Illness Index
KW  - Treatment Outcome
KW  - MedStar Washington Hospital Center
KW  - Medicine/Pulmonary-Critical Care
KW  - Journal Article
KW  - Review
N2  - There are three major problems with asthma care in the USA and misuse of asthma drug therapy contributes to each. Asthma patients suffer from symptoms regularly partly because healthcare providers do not understand the Expert Panel Report III (EPR3) recommendations on assessing asthma symptoms to determine drug treatment and, consequently, undertreat the disease. Asthma patients experience exacerbations often in part because the EPR3 provides limited guidance on using exacerbation risk to guide asthma treatment, again leading to undertreatment. The EPR3 recommends inhaled corticosteroids as the preferred therapy for mild persistent asthma but American healthcare providers disregard this recommendation based on different perceptions about the risks and benefits of inhaled corticosteroids and choose drug treatments with higher healthcare costs
UR  - http://dx.doi.org/10.1586/ers.13.27
ER  -